INTRODUCTION
The foundational premise of artificial intelligence regulation in India has always been that the computing system and the human being are distinct legal entities. The machine processes data; the human possesses rights. This fundamental dichotomy is now collapsing. With the emergence of human brain organoids and their experimental integration into biological computing systems, this traditional distinction is becoming increasingly difficult to maintain.
Laboratory systems built from human stem cells can now sustain organised neural activity for years[1] and participate in closed-loop computation. A brain organoid may begin as a stem-cell derivative, yet later be connected to electrodes, trained through repeated inputs and incorporated into a computational system.[2] These systems, when used as developmental models and as organoid intelligence when harnessed for biological computing, sit uneasily between research material and something closer to a hybrid computational substrate. This innovation has pushed biotechnology into a profound regulatory grey area.
The immediate legal question is not whether India has enacted a “brain organoid law.” It has not. The more difficult question is whether existing rules, designed for stem cells, human participant research, biosafety, data and medical products, can adequately govern increasingly complex biological computing systems.
FROM BRAIN MODELS TO BIOLOGICAL COMPUTING
Human brain organoids are three-dimensional structures generated from human pluripotent stem cells, including induced pluripotent stem cells. They can reproduce selected features of developing brain tissue, including aspects of cellular differentiation, organisation and electrical activity. They are not miniature human brains. They generally lack the vascular, sensory, bodily and environmental integration of an actual brain.[3]
Organoid intelligence refers to the experimental use of living neural tissue as part of a computing architecture. The tissue may be connected to electrodes, software, machine learning systems or simulated environments. Its function is not merely to model disease or test drugs; it may participate in information processing through biological activity and plasticity.
That distinction matters legally. Conventional organoid research primarily raises questions about donor material, consent, stem-cell oversight and biosafety. OI adds questions about system ownership, data, responsibility, validation and the consequences of placing living neural tissue inside an adaptive technological system.
INDIA’S DISTRIBUTED FRAMEWORK
The National Guidelines for Stem Cell Research, 2017 are the most directly relevant Indian framework. Brain organoids produced from human pluripotent stem cells would likely fall within the practical reach of the guidelines because they involve the derivation, culture, differentiation and use of human stem-cell material or its derivatives.[4]
The guidelines require informed consent before procuring biological material for stem-cell isolation and establish institutional oversight mechanisms, including the Institutional Committee for Stem Cell Research. They also address restrictions, material transfer, monitoring and the distinction between research and clinical use.
Yet the guidelines were not written specifically for cerebral organoids. They do not expressly define brain organoids, organoid intelligence, biological computing, neural complexity or consciousness. Their application is therefore indirect. They regulate the biological origin and research pathway, not the legal status of the mature organoid or the integrated OI system.
The legal status of these instruments is also more complex than calling them either statutes or voluntary guidance. In Yash Charitable Trust v. Union of India, decided by the Supreme Court in January 2026, while treating the matter as part-heard, the Court recognised that relevant ICMR ethical requirements can acquire binding consequences through incorporation into the New Drugs and Clinical Trials Rules, 2019. The judgment rejects the assumption that failure to fit one regulatory category such as “new drug” necessarily creates a legal vacuum.[5]
The institutional structure has also changed. In 2024, the Department of Health Research dissolved the National Apex Committee for Stem Cell Research and Therapy and shifted much of the immediate review to institutional Ethics Committees subject to specified stem-cell expertise and DHR registration. The Supreme Court later held that executive action could not remove DHR oversight preserved by statutory rules.[6] For advanced neural organoid research, this exposes another gap. Stem-cell expertise does not necessarily include electrophysiology, computational learning, neural complexity or neuroethics.
THE LEGAL STATUS OF THE ORGANOID
What exactly is a human brain organoid in Indian law? The available framework does not provide a single answer. Depending on context, it may be treated as human biological material, a stem-cell derivative, a research specimen, a genetically engineered cell-based product, or a component of a regulated medical technology. None of these classifications fully captures the object.
Its status may also change according to how it is created and used. A simple, immature organoid used for developmental research presents a different regulatory concern from a mature organoid connected to sensory inputs, a closed-loop computational system or an animal host. Regulation based only on the fact that the cells came from a human donor would miss these functional differences. This produces a central category mismatch. Existing rules are organised around the source of material, the research process or the intended product. OI requires attention also to what the biological system can do.
Indian law has not presently classified such an organoid as a person, embryo, human organ or sui generis legal entity. Nor has an Indian court decided whether an organoid has rights or whether its biological activity can itself be legally protected.
CONSENT, OWNERSHIP AND DATA
Consent becomes difficult across that transformation. A donor may agree to biomedical research using donated cells, but that does not automatically answer whether the donor meaningfully contemplated indefinite storage, neural differentiation, closed-loop training, commercial biological computation or cross-border transfer. The 2017 ICMR ethical framework recognises broad consent as one possible model for permitting future not fully specified research uses of stored biological material alongside more specific and tiered forms of consent.[7]
This does not mean donors automatically own finished organoids. Ownership of biological material must be distinguished from intellectual-property rights over inventions, processes, hardware, software and data. Indian law does not presently establish a settled proprietary rule for a transformed brain organoid.
India’s Digital Personal Data Protection Act, 2023 does not separately define genomic, health or neural data; its relevant concept is digital personal data relating to an identifiable individual. Further, as of August 2026, most of the Act’s substantive processing obligations and corresponding rules have not yet commenced, while Indian law contains no distinct statutory category of “neural data”.[8]
MORAL STATUS AND WELFARE
As these systems become more complex, the legal conversation inevitably touches upon the moral status of the organoid. Recently, the Asia Pacific Neuroethics Working Group’s 2026 consensus considered it premature to attribute sentience or other morally significant consciousness to present brain organoids, while also cautioning that future developments should continue to be monitored.[9]
Indian law does not presently recognise brain organoids as legal persons, nor has the available Indian jurisprudence established a settled proprietary classification for them. No identified Indian authority extends Article 21 rights to brain organoids, and the Prevention of Cruelty to Animals Act, 1960 does not expressly address in-vitro human neural organoids.[10]
OI IS NOT ORDINARY AI
OI exposes a gap between biomedical and AI governance. AI frameworks focus on software, algorithms, data and deployers. Stem-cell and biomedical frameworks focus on donors, cells, research procedures and safety. An OI system combines both while being fully captured by neither. The same fragmentation affects liability. Harmful clinical OI outputs may engage negligence, product liability, device, research and professional standards; commercial non-medical deployment is less clear. No Indian OI-specific liability regime presently allocates responsibility across biological and software components. This distinction also exposes the limits of regulating OI purely as AI.
COMPARATIVE SIGNALS
China issued national ethical guidelines for human organoid research in April 2025 that call for ethical risk assessment and continued monitoring of brain-organoid electrophysiological activity and complexity.[11] The United Kingdom’s Nuffield Council on Bioethics and the Asia Pacific Neuroethics Working Group have likewise advanced anticipatory and proportionate approaches to emerging neural-organoid risks, indicating growing international attention to complexity-sensitive oversight rather than a settled global regulatory model.[12]
CONCLUSION
India does not presently need to leap directly to a sweeping “Brain Organoid Act”. A more realistic response would begin within existing institutions. ICMR, DHR and DBT could develop dedicated neural-organoid and OI guidance distinguishing routine organoid research from advanced closed-loop, embodied, genetically modified or clinically deployed systems.
Oversight should be tiered. Ordinary disease-modelling organoids need not be regulated as though they were conscious entities. More complex systems could trigger enhanced review based on maturation, integration, transplantation, closed-loop learning, embodiment or clinical use. Institutional committees reviewing such work should also have access to expertise beyond conventional stem-cell science, particularly computational neuroscience, electrophysiology, AI safety and neuroethics.
Consent rules should identify transformative uses requiring enhanced disclosure or renewed consent, especially commercial OI, transplantation, significant genetic manipulation and long-term biological computing. India could also develop clearer standards for organoid-related data, transfer agreements, advanced research registration and future welfare monitoring.
India’s present position is therefore neither adequate regulation nor complete absence of regulation. It is fragmented regulation with a growing category mismatch. Stem-cell rules govern origin, ethics guidance governs participation, biosafety rules govern certain modifications, data law governs some digital records, and product law may govern later uses. What remains unclear is the status of the integrated biological-computing system itself.
The unresolved question is whether law can continue to treat “human biological material” and “intelligent system” as separate categories once living neural tissue occupies both roles at the same time.
Author(s) Name: Adityasinh Ranjitsinh Ghatge (New Law College, BVDU, Pune)
References:
[1] Irene Faravelli et al., ‘Human brain organoids record the passage of time over multiple years’ (2026) Nature <https://doi.org/10.1038/s41586-026-10877-x> accessed 24 August 2026
[2] Hongwei Cai et al., ‘Brain organoid reservoir computing for artificial intelligence’ (2023) 6 Nature Electronics 1032 <https://www.nature.com/articles/s41928-023-01069-w> accessed 24 August 2026; Lena Smirnova et al., ‘Organoid intelligence (OI): the new frontier in biocomputing and intelligence-in-a-dish’ (2023) 1 Frontiers in Science 1017235 <https://www.frontiersin.org/journals/science/articles/10.3389/fsci.2023.1017235/full> accessed 24 August 2026
[3] National Academies of Sciences, Engineering, and Medicine, The Emerging Field of Human Neural Organoids, Transplants, and Chimeras: Science, Ethics, and Governance (National Academies Press 2021) 13, 29–30
[4] ICMR National Guidelines for Stem Cell Research 2017, ss 2, 4.1.1, 5, 15 and 17
[5] Yash Charitable Trust v Union of India (2026) INSC 96 [118]–[123], [154]–[155]
[6] Ibid [133]–[138], [151(xi)]–[151(xii)]
[7] ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017
[8] Digital Personal Data Protection Act 2023, ss 2(n), 2(t); Digital Personal Data Protection Rules 2025, r 1(4)
[9] Shu Ishida et al., ‘Ethics and Regulation of Human Brain Organoid Research: Recommendations from the Asia Pacific Neuroethics Working Group’ (2026) 18 Asian Bioethics Review 649 <https://link.springer.com/article/10.1007/s41649-025-00398-6> accessed 24 August 2026
[10] Prevention of Cruelty to Animals Act 1960, s 2(a)
[11] National Science and Technology Ethics Committee, Life Sciences Ethics Subcommittee, ‘人源类器官研究伦理指引 [Ethical Guidelines for Human Organoid Research]’ (Ministry of Science and Technology of the People’s Republic of China, 01 April 2025) <https://most.gov.cn/kjbgz/202504/W020250429607536270108.pdf> accessed 24 August 2026
[12] Neural organoids: Ethical and governance considerations (Nuffield Council on Bioethics 2026); Ishida (n 9)